Neurogen Commences Sleep Maintenance Phase II Clinical Trial In Chronic Insomnia
Thu, 21 Dec 2006 08:00 AM EST
... Neurogen Corporation (Nasdaq: NRGN) today announced that it has commenced a Phase II clinical trial in chronic insomnia patients with the Company's insomnia agent, NG2-73. The study will measure sleep maintenance, as well as onset, across a range of doses and formulations. [click link for full article] ...
Related Topics
- Clinical Trials
- Insomnia
- Sleep Disorders
- Sleep Apnea
- Apnea
- Chronic Fatigue Syndrome
- Chronic Pain
- Pain - Chronic
- Chronic Diseases
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Tiagabine
- Tarceva
- Quetiapine
- Trazodone
- Mirtazapine
- Doxylamine
- Nystatin and Triamcinolone
- Food Recommendations: South Beach Diet - Phase 1

Not Signed In -


